AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics to expand its immunology drug portfolio.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
AbbVie is set to acquire Apogee Therapeutics in a deal valued at $10.9 billion. The acquisition is framed as a strategic effort to enhance the company's research and presence within the immunology sector.
Coverage from Fierce Biotech, The Wall Street Journal, CNBC, and the AbbVie News Center emphasizes the transaction's focus on bolstering the firm's growth in immunology. Reports highlight the inclusion of a specific eczema drug candidate as a primary component of the deal.
Future developments will depend on the finalization of the acquisition process. Coverage does not yet specify the anticipated closing date for the transaction or the specific regulatory hurdles that may remain.
Synthesized by PULSE from the headlines below under a strict no-invention contract. Updated 50d ago.
Quick answers
What is the total value of the acquisition?
The acquisition of Apogee Therapeutics by AbbVie is valued at $10.9 billion.
What is the strategic goal of the purchase?
AbbVie intends to deepen its immunology portfolio, specifically acquiring an eczema drug prospect.
Which organizations are involved?
The companies involved in this transaction are AbbVie and Apogee Therapeutics.
Coverage (7)
- AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs BioPharma Dive · 50d ago
- AbbVie (ABBV) Is Buying Apogee Therapeutics For $10.9 Billion Yahoo Finance · 50d ago
- AbbVie to acquire Apogee Therapeutics in $10.9B deal Yahoo Finance · 50d ago
- AbbVie inks $10.9B Apogee buyout to bag hotly tipped eczema prospect Fierce Biotech · 50d ago
- AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion WSJ · 50d ago
- AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push CNBC · 50d ago
- AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio AbbVie News Center · 50d ago
Topics
Related trends
Hanwha Defense USA seeks to acquire Austal USA in $1.2B potential deal
Hanwha Defense USA is pursuing a $1.2 billion acquisition of Austal USA, signaling a strategic shift in the American shipbuilding landscape.
Here’s Why Nvidia Stock Is Down Today
Nvidia's shifting role in the AI ecosystem coincides with rising global commodity volatility following new US demands on Iran.
Scientists discover what may be behind Alzheimer’s
New research into brain immune cell turnover around age fifty provides unprecedented clues regarding the progression of Alzheimer's disease.
Teledyne to Acquire Varex Imaging Corporation
Teledyne Technologies announces a definitive agreement to acquire Varex Imaging Corporation in a transaction valued at $1.1 billion.
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
MoonLake Immunotherapeutics reports that its nanobody drug, sonelokimab, successfully met all clinical endpoints in a Phase 3 trial for psoriatic arthritis.
Barrick, Newmont settle dispute with $1.95B deal
Mining giants Barrick and Newmont have resolved a legal dispute through a settlement agreement valued at $1.95 billion.